Trial Profile
Long-Term Efficacy of Omalizumab in Patients with Treatment-Resistant Chronic Spontaneous Urticaria
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Urticaria
- Focus Therapeutic Use
- 07 Aug 2015 New trial record